<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865488</url>
  </required_header>
  <id_info>
    <org_study_id>AA-GYN-002</org_study_id>
    <nct_id>NCT00865488</nct_id>
  </id_info>
  <brief_title>Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery</brief_title>
  <official_title>A Prospective, Controlled, Randomized, Multi-Center, Pivotal Study Evaluating the Safety and Efficacy of AdhexilTM in Prevention And/Or Reduction of Adhesions in Gynecology Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OMRIX Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OMRIX Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of ADHEXIL™ in preventing
      and/or reducing post-operative adhesions in patients undergoing surgery involving the
      ovaries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be divided into two arms: 1) patients who will be treated in accordance with
      standard of care; 2) patients for which ADHEXIL™ will be applied on one ovary and fallopian
      tube.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adhesions will be assessed according to incidence, extent and severity.</measure>
    <time_frame>8 weeks post surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ovarian Cysts</condition>
  <condition>Endometriosis</condition>
  <condition>Adhesions</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients who will be treated in accordance with standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients for which Adhexil will be applied to prevent/reduce adhesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADHEXIL</intervention_name>
    <description>Adhesions prevention</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged 18-45 years at screening.

          -  Patients undergoing elective laparoscopic surgery involving at least one adnexa.

        Exclusion Criteria:

          -  Pregnant (including ectopic pregnancy) or breastfeeding patient.

          -  Patients with a documented diagnosis of cancer.

          -  Patients with a lymphatic, hematologic or coagulation disorder.

          -  Patients with a known or suspected hypersensitivity to blood, blood products or any
             constituent of Adhexil™.

          -  Patients who are immunocompromised, possess autoimmune disorders, or who are routinely
             taking anticoagulants.

          -  Patients who have participated in another clinical study within 30 days of enrolment.

          -  Investigator's opinion that the patient is medically unfit or would be at major risk
             if enrolled into the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eran Kurman, B.med.Sc, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>OMRIX Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>December 20, 2009</last_update_submitted>
  <last_update_submitted_qc>December 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Eran Kurman, Clinical Affairs Manager</name_title>
    <organization>Omrix Biopharmaceuticals Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

